Introduction

Introduction

​​Bright Green Corporation is breaking new ground in domestic production of plant-based medicines in the United States. Committed to sustainable high-tech agriculture, manufacturing, and research—a foundation built from a legacy of cannabis expertise and operations— Bright Green is a federally-authorized manufacturer of Active Pharmaceutical Ingredients (APIs) and plant-based drugs. With substantial ongoing support from the U.S. Congress to reduce reliance on foreign imports, Bright Green is at the forefront of the “Drugs Made in America” movement.

Our Mission

As operations expand at Bright Green’s 1 million sq ft Grants, New Mexico Facility to concentrate on the research, production, manufacture, and distribution of APIs, plant-based drugs, and Cannabis, compliance remains a key part of its ethos. Enabled by a New Mexico Board of Pharmacy application, and operating in full alignment with federal regulations including obtaining DEA registrations for new controlled substances, Bright Green has quickly emerged as a leader in the USD $27.97 Billion global plant-based API market—with a projected CAGR of 6% from 2023 to 2030.

As the sole business of this scale capable of meeting market demand, Bright Green is dedicated to securing long-term federal government contracts to establish a reliable domestic API supply chain, helping to diminish U.S. dependency on foreign drug imports and deliver exceptional value to shareholders.

Our Vision

With a vision to enhance the quality of life across demographics, Bright Green looks to solidify its role as a key supplier in new drug markets, including cannabis APIs for the FDA-regulated drug industry. The company’s plan for strategic growth emphasizes extensive research and development into medicinal applications of plant-based therapies, addressing health, medication costs, and reducing water usage through advanced climate control technology in its growing facility—powered by 100% clean, renewable energy.
In an exclusive partnership with Asia Capital Pioneers Group (ACPG), Bright Green corporation has implemented a monumental USCIS EB-5 program to raise $500 million for the expansion of our high-security, advanced glass Greenhouse facilities to produce plant-based drugs with consistent high standards of quality and purity.

EB-5 Offering

$575,000,000

Per EB-5 Applicant

$880,000

Structure

Equity

Regional Center

Regional Center Bright Green LLC

Term

3 Years

I-956F Exemplar

USCIS Receipt Issued

I-526E Fillings

Now available

Asia Capital Pioneers Group Inc. (ACPG), an Asia-based investment firm specializing in global investments in high-growth industries, announced an exclusive partnership with Bright Green Corporation—a NASDAQ company authorized for U.S. medical cannabis manufacturing and distribution. ACPG will connect eligible Asia-Pacific investors to the U.S. EB-5 immigration investor program, facilitating access to U.S. Green Card residency with a qualifying investment of USD $880,000. The program focuses on foreign investments for advanced agricultural facilities in rural New Mexico, the only one of its kind in the state, approved by USCIS.